BioVie Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $12.3M
- Price
- $1.44
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.37%
- Volume
- 135.1K
About
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Quick stats
Shares outstanding8.5M
Computed float8.4M
Float / shares98.8%
Cash runway (months)3.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001580149
Websitehttps://bioviepharma.com
AI Summary
AI-generated1/35
minorneutralother
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
New to The Street Show 773 airs tonight on Bloomberg Television and features an interview with BioVie CEO Cuong Do.
Do reviews topline results from the Phase 2 ADDRESS-LC trial of bezisterim in Long COVID, highlighting improvements in fatigue, post-exertional malaise and cognitive impairment, with a planned FDA End-of-Phase 2 meeting ahead.
The segment is media exposure rather than new disclosure; the trial results were previously announced and no new clinical or financial data appears in this release.